FierceBiotech

Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock ...
FierceBiotech

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Nasdaq

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
Business Wire

Infiniti’s Clinical Landscape Study Helped a Healthcare Company to Expand Treatment Portfolios Specific to Crohn’s Disease | RFP for Similar Engagements for Your Business

LONDON--(BUSINESS WIRE)--Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on clinical landscape study for a ...
Business Wire

Infiniti’s Market Assessment Study Helped a Medical Implants Supplier Gain 11% Market Share in its New Product Category | Read the Complete Success Story to Gather Detailed ...

LONDON--(BUSINESS WIRE)--Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market assessment study. This success ...